Tackling the Last Mile: A Major Component to Successfully Establish Radioligand Therapy.
作者信息
Pomykala Kelsey L, Würker Marcus, Herrmann Ken
机构信息
Institute for Artificial Intelligence in Medicine, University Hospital Essen, Essen, Germany;
Deutsche Post DHL Group, Bonn, Germany; and.
出版信息
J Nucl Med. 2023 Mar;64(3):347-348. doi: 10.2967/jnumed.122.264900. Epub 2022 Dec 22.
Abstract
摘要
相似文献
1
Tackling the Last Mile: A Major Component to Successfully Establish Radioligand Therapy.
J Nucl Med. 2023 Mar;64(3):347-348. doi: 10.2967/jnumed.122.264900. Epub 2022 Dec 22.
2
Tackling the "last mile" problem in renovation waste management: A case study in China.
Sci Total Environ. 2021 Oct 10;790:148261. doi: 10.1016/j.scitotenv.2021.148261. Epub 2021 Jun 9.
3
[Reducing occupational burnout and enhancing job performance in new nurses: the efficacy of "last mile" programs].
Hu Li Za Zhi. 2012 Aug;59(4):30-42. doi: 10.6224/JN.59.3.30.
4
Sexual and reproductive health and rights of "last mile" adolescents: a scoping review.
Sex Reprod Health Matters. 2022 Dec;30(1):2077283. doi: 10.1080/26410397.2022.2077283.
5
Complex emergencies: overcoming barriers to health care.
Scand J Public Health. 2022 May;50(3):312-317. doi: 10.1177/1403494821993693. Epub 2021 Feb 24.
6
Last mile research: a conceptual map.
Glob Health Action. 2021 Jan 1;14(1):1893026. doi: 10.1080/16549716.2021.1893026.
7
ParcEMon: IoT Platform for Real-Time Parcel Level Last-Mile Delivery Greenhouse Gas Emissions Reporting and Management.
Sensors (Basel). 2022 Sep 28;22(19):7380. doi: 10.3390/s22197380.
8
Last-mile-as-a-service (LMaaS): An innovative concept for the disruption of the supply chain.
Sustain Cities Soc. 2021 Dec;75:103310. doi: 10.1016/j.scs.2021.103310. Epub 2021 Aug 28.
9
An analysis of the validity of the three-mile run as a field test of aerobic capacity in college males.
Res Q Exerc Sport. 1990 Sep;61(3):233-7. doi: 10.1080/02701367.1990.10608684.
10
Bridging the "last mile" gap between AI implementation and operation: "data awareness" that matters.
Ann Transl Med. 2020 Apr;8(7):501. doi: 10.21037/atm.2020.03.63.
本文引用的文献
1
How Many Theranostics Centers Will We Need in the United States?
J Nucl Med. 2022 Jun;63(6):805-806. doi: 10.2967/jnumed.122.264144.
2
Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre.
Eur J Nucl Med Mol Imaging. 2022 Jun;49(7):2300-2309. doi: 10.1007/s00259-022-05785-x. Epub 2022 Apr 11.
3
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
N Engl J Med. 2021 Sep 16;385(12):1091-1103. doi: 10.1056/NEJMoa2107322. Epub 2021 Jun 23.
4
[Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Lancet. 2021 Feb 27;397(10276):797-804. doi: 10.1016/S0140-6736(21)00237-3. Epub 2021 Feb 11.
5
Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer: A Meta-analysis.
Clin Nucl Med. 2018 Oct;43(10):728-734. doi: 10.1097/RLU.0000000000002210.
6
[Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.
Lancet Oncol. 2018 Jun;19(6):825-833. doi: 10.1016/S1470-2045(18)30198-0. Epub 2018 May 8.
Zotero 插件